The global private equity market is poised to embark on a new phase of recovery by 2026, following a period of post-pandemic strain characterized by elevated interest rates, stringent credit conditions, and subdued exit and distribution activities for investors.
According to J.P. Morgan Asset Management’s “Alternative Investments Outlook 2026” report, dated Saturday, May 16, 2026, the normalization of credit markets, declining interest rates, and a resurgence in merger and acquisition (M&A) activities are identified as the primary catalysts for this anticipated global private equity resurgence. J.P. Morgan highlights that throughout 2025, discernible signs of market normalization began to emerge. This period saw a rise in initial public offering (IPO) and M&A activities, alongside a reinvigorated venture capital market, largely propelled by advancements in the technology sector, particularly in artificial intelligence (AI).
“Private equity is entering 2026 equipped with essential elements to bolster dealmaking,” states J.P. Morgan in its report, “ranging from valuation stabilization and the reopening of credit markets to significantly improved investor sentiment.”
Furthermore, J.P. Morgan identifies two pivotal factors poised to shape the private equity market in 2026. Firstly, an anticipated surge in transaction activity and liquidity opportunities as buyers, sellers, and lenders re-engage actively with the market. Secondly, the emergence of a new wave of innovation, particularly within the AI and healthcare sectors, which is expected to unlock substantial long-term value creation.
The report further underscores that the normalization of valuation expectations is progressively narrowing the price gap between sellers and buyers, a disparity that had effectively frozen transaction markets since 2022. Concurrently, the credit market is demonstrating signs of robust recovery. A reduction in loan spreads is rendering leveraged buyout (LBO) financing more appealing, particularly for transactions within the small and middle market segments. J.P. Morgan’s data indicates that in 2023, 78% of direct lending transactions were priced at SOFR plus 600 basis points. However, by 2025, approximately 50% of transactions had fallen below SOFR plus 500 basis points, clearly signaling a reduction in funding costs.
The small and middle market segment, in particular, is highlighted as one of the most compelling investment areas for 2026. Companies within this segment are perceived as more agile, boast lower valuations, and offer greater potential for value creation through operational enhancements, rather than solely depending on leverage. “Small and middle market companies are typically still owned by families or founders, presenting significant opportunities for business professionalization, efficiency gains, and strategic expansion through M&A,” the report elaborates.
Furthermore, the secondary private equity market is also forecasted to experience robust growth, with global transaction values reaching US$160 billion in 2024 and projected to surpass US$200 billion in 2025.
Shifting focus, J.P. Morgan posits that the AI sector will emerge as a central nexus for novel value creation within private markets. A growing number of technology companies are now opting to remain private for extended periods, rather than pursuing immediate public listings. For instance, OpenAI, which introduced ChatGPT approximately three years ago, now commands a valuation reaching US$500 billion. Similarly, AI infrastructure powerhouses like Databricks have surpassed valuations of US$100 billion. “Value creation in the technology sector is increasingly shifting from public markets to private markets,” J.P. Morgan notes. The report further underscores AI’s immense potential impact on the global economy. Current worldwide information technology (IT) spending, estimated at US$5 trillion, is projected to surge to US$15 trillion within the next decade.
Beyond technology, the healthcare sector is also recognized as a significant wellspring of innovation within private markets. Advancements such as CRISPR-based genetic therapies, the application of AI in drug discovery, and the ongoing progress in precision medicine are collectively paving the way for substantial long-term growth opportunities. J.P. Morgan suggests that current market conditions present an compelling window for investors, as healthcare sector valuations have undergone considerable correction even as scientific innovation in the field accelerates robustly.
“2026 holds the potential to be a highly promising year for private equity, bolstered by improving liquidity and continuously evolving innovation,” J.P. Morgan concludes.
Summary
The global private equity market is projected to enter a phase of recovery by 2026, driven by normalizing credit conditions, declining interest rates, and a resurgence in merger and acquisition activity. J.P. Morgan’s outlook highlights that stabilized valuations and improved investor sentiment are bridging the price gap between buyers and sellers, while lower funding costs are revitalizing leveraged buyouts. Small and middle-market companies are specifically identified as key areas for growth due to their agility and potential for operational professionalization.
Innovation, particularly in artificial intelligence and healthcare, is acting as a primary catalyst for long-term value creation within private markets. As technology firms increasingly choose to remain private for longer, significant capital is migrating away from public exchanges toward high-growth, private AI infrastructure and advanced genetic therapies. With the secondary market also experiencing robust growth, 2026 is positioned to offer compelling opportunities for investors seeking to capitalize on enhanced liquidity and technological advancement.